Effect analysis of low molecular weight heparin anticoagulation in the treatment of ICU sepsis
低分子肝素抗凝治疗ICU脓毒症的效果分析

摘要

目的 探讨低分子肝素抗凝治疗ICU脓毒症的效果。方法 选取2017年1月至2021年12月间在我院接受治疗的50例ICU脓毒症患者，随机分为两组，每组各25例。参照组采用常规药物治疗,研究组采用低分子肝素抗凝。比较分析两组患者的治疗有效率及不良反应发生率。结果 研究组患者的治疗效果优于参照组患者，数据差异有统计学意义（P<0.05）。研究组患者治疗后不良反应发生率低于参照组患者，数据差异有统计学意义（P<0.05）。两组患者治疗后的凝血功能指标（PT、APTT、FIB）均优于治疗前，且研究组患者治疗后的凝血功能指标（PT、APTT、FIB）均优于参照组，差异有统计学意义（P＜0.05）。结论 对ICU脓毒症患者治疗采用低分子肝素抗凝，其临床治疗效果显著,优于常规药物治疗，值得临床进一步推广。

Abstract

Objective To investigate the effect of low molecular weight heparin anticoagulation in ICU sepsis.
Methods Fifty patients with ICU sepsis treated in our hospital from January 2018 to June 2021 were randomly divided into two groups, with 25 patients in each group. The reference group was treated with conventional drugs, and the study group used low molecular weight heparin anticoagulation. Comparative analysis of the treatment response rate and the incidence of adverse reactions in the two groups.
Results The treatment effect of the patients in the study group was better than that of the patients in the reference group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group after treatment was lower than that in the reference group, and the difference was statistically significant (P<0.05). The coagulation function indexes (PT, APTT, FIB) of the two groups of patients after treatment were better than those before treatment, and the coagulation function indexes (PT, APTT, FIB) of the study group after treatment were better than those of the reference group, and the difference was statistically significant (P<0.05).
Conclusion   The use of low molecular weight heparin anticoagulation in the treatment of ICU sepsis patients has a significant clinical effect, which is better than conventional drug treatment, and is worthy of further clinical promotion.